These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38986791)
1. Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus. Brewer J; Wilson M; Coons JC; Schmit A; Whittenhall ME; Kimber A; Broderick M; Lee D; Patzlaff N; Miller C; Ataya A; LaRoy V; King CS; Ravichandran AK; Kingrey JF; Sahay S Respir Med; 2024 Sep; 231():107734. PubMed ID: 38986791 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
3. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
4. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. Coons JC; Miller T Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511 [TBL] [Abstract][Full Text] [Related]
5. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry. Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194 [TBL] [Abstract][Full Text] [Related]
8. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
9. Inpatient Initiation of Oral Treprostinil in an Academic Medical System. Hohlfelder B; Tonelli AR; Heresi GA; Bair N; Rahaghi FF; Bauer SR Cardiovasc Drugs Ther; 2020 Aug; 34(4):547-553. PubMed ID: 32424651 [TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF; Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604 [No Abstract] [Full Text] [Related]
11. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series. Fanous SM; Janmohamed M Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721 [TBL] [Abstract][Full Text] [Related]
12. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
13. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Rahaghi FF; Allen RP; Balasubramanian VP; Chakinala MM; Elwing JM; Feldman J; Leary PJ; Rischard F; Safdar Z; Sood N; Oudiz RJ Pulm Pharmacol Ther; 2021 Feb; 66():101979. PubMed ID: 33259923 [TBL] [Abstract][Full Text] [Related]
16. Oral treprostinil in the treatment of pulmonary arterial hypertension. Feldman J; Habib N; Radosevich J; Dutt M Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725 [TBL] [Abstract][Full Text] [Related]
18. Oral treprostinil for the treatment of pulmonary arterial hypertension. de Lartigue J Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906 [TBL] [Abstract][Full Text] [Related]
19. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. Sarangarm P; Elwood K Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906 [TBL] [Abstract][Full Text] [Related]
20. Treprostinil for pulmonary hypertension. Skoro-Sajer N; Lang I; Naeije R Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]